Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523

Next Previous
Search
Trial Profile

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sovleplenib (Primary)
  • Indications Autoimmune disorders; Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Hutchison MediPharma

    • Most Recent Events

    • 06 Dec 2016 According to a Hutchison MediPharma media release, data from this trial was presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals.
    • 14 Nov 2016 Results published in the Chi Med Media Release
    • 14 Nov 2016 Data from this trial will be presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals as reported by a Chi Med media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top